Anti-Aging Drugs Enter Human Trials: Aging Intervention Research Fully Underway

Senolytics, mTOR inhibitors, and NAD+ enhancers show clinical trial results in the longevity field

Longevity medicine has transitioned from "anti-aging concept" to rigorous clinical trial validation in 2025-2026. The FDA has formally established "aging itself" as an intervenable medical indicator, rather than only treating aging-related diseases.

Clinical Progress of Three Major Pharmacological Pathways

1. Senolytics (Senescent Cell Clearers): Eliminate senescent cells that have stopped dividing but continue to secrete pro-inflammatory factors.

Unity Biotechnology's UBX1325 (Bcl-xL inhibitor) achieved the primary endpoint of improved best-corrected visual acuity (BCVA) in a Phase 2 trial for diabetic macular edema, though progress has since stalled
Mayo Clinic-led DAS-181 regimen (dasatinib + quercetin): In patients with interstitial lung fibrosis, 6-minute walk distance increased by 21 meters after 12 weeks of treatment (p = 0.03), with senescent cell marker p16INK4a decreasing by 45%
The SENECA trial launched in 2026: evaluating fisetin for frailty index improvement in 500 adults >70 years old

2. mTOR Inhibitors: Rapamycin and its analogs (rapalogues) are the most widely studied longevity intervention drugs.

AgelessRx's TRIIM-X trial: Low-dose rapamycin (5mg weekly) in healthy 60-70 year olds showed significant improvement in immune aging markers (T cell receptor diversity) after 12 months, with PD-1 expression in CD8+ T cells decreasing by 30%
TAME (Targeting Aging with Metformin) Phase 3 trial enrolling 3,000 adults aged 65-80, evaluating whether metformin can delay the composite aging endpoint (death, dementia, cardiovascular events, cancer), with results expected in 2027

3. NAD+ Enhancers: Boosting cellular energy metabolism and DNA repair capacity through NAD+ precursor supplementation (NMN, NR).

Waseda University / University of Tokyo joint trial: Oral NMN (250mg/day) for 12 weeks increased 6-minute walk distance by 12% in elderly men, with improved insulin sensitivity (HOMA-IR decreased by 18%)
Chromadex's NR supplement (Niagen) did not meet the primary endpoint of Alzheimer's prevention in Phase 2, but achieved significant improvements in blood NAD+ levels and mitochondrial function markers (NAD+ levels increased by 50%)

New Standards for Biological Age Assessment

The core challenge of longevity clinical trials is "what metrics to use for measuring aging intervention effects." In 2025, multiple institutions reached consensus on the following composite assessment framework:

First-generation clocks: DNA methylation age (Horvath clock, GrimAge) — change cycle of 6-12 months
Second-generation clocks: Proteomic age + metabolomic age + immune age — more sensitive, change cycle of 3-6 months
Functional metrics: 6-minute walk, grip strength, gait speed, cognitive scores — clinically meaningful gold standards

Market and Outlook

The global longevity medicine market (including supplements, drugs, diagnostics) is projected to grow from $30 billion in 2025 to $60 billion by 2030. However, the FDA has not yet established a complete regulatory pathway for "longevity" as an indication — most longevity drugs are currently filed under "specific indications" (such as interstitial lung disease, immune aging, muscle wasting). If the TAME trial succeeds, it could provide a regulatory precedent for "aging as an indication," fundamentally transforming the approval landscape for anti-aging drugs.

POC.HK Future Technology Observatory — Independent Technology Watch Report